Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
LAMIVUDINE TABLETS (HBV). These highlights do not include all the information needed to use LAMIVUDINE TABLETS (HBV) safely and effectively. See full prescribing information for LAMIVUDINE TABLETS (HBV). LAMIVUDINE tablets (HBV) for oral use Initial U.S. Approval: 1995
Medication labelWhy this: Advisory · dailymed-prescription
Lamivudine tablets (HBV) are indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [ see Clinical Studies ( 14.1, 14.2) ]. The following points should be considered when initiating therapy with lamivudine tablets (HBV): Due to high rates of resistance development in treated patients, initiation of treatment with lamivudine tablets (HBV) should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. Lamivudine tablets (HBV) have not been evaluated in patients co-infected withhuman immunodeficiency virus(HIV), hepatitis C virus (HCV), or hepatitis delta virus. Lamivudine tablets (HBV) have not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease.
- generic_name
- lamivudine
- product_names
- Lamivudine
- ndc
- 51407-866, 60505-3250, 51407-866-60
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en